LifeVantage Reports Full Clinical Results Including Average of 140% Increase in GLP-1 with the MindBody GLP-1 System™Ω
29 Oktober 2024 - 9:05PM
LifeVantage Corporation (Nasdaq: LFVN), a leader in health and
wellness solutions designed to activate optimal health processes at
the cellular level, today announced groundbreaking results from a
human clinical trial performed on the new MindBody GLP-1 System™.
Results from the trial included a 140% average increase in GLP-1
levels in the body leading to an average weight loss of 9 pounds in
8 weeks and up to 25 pounds in 12 weeks in participants. Ω ‡
Production of GLP-1 (glucagon-like peptide-1) in
the body declines due to age, poor diet, stress, or other lifestyle
factors. The decline can cause cravings, false hunger, and weight
gain. The MindBody GLP-1 System uses naturally-sourced ingredients
to directly activate natural GLP-1 production in L-cells,
supporting that activation indirectly by optimizing the gut
microbiome to create short-chain fatty acids and fuel production.
Ω*
The 12-week human clinical trial began in early
June 2024 and set out to investigate if, through these mechanisms
of action, the MindBody GLP-1 System could holistically and
sustainably increase GLP-1 hormone levels in overweight adults,
without unwanted side effects.*
The study was conducted by independent
researchers at Lighthouse Research. Sixty subjects ages 31–78 years
with a BMI≥25 were randomized into three groups: a control group
with no product use, a group using the MindBody GLP-1 System
without diet and exercise guidelines, and a group using the
MindBody GLP-1 System with diet and exercise guidelines.
Subjects were evaluated every 4 weeks. Visits
included anthropometric and biometric measurements, before and
after photographs, food behavior questionnaires, and blood work for
GLP-1 analysis.
Key 12-week findings from the human trial
include:
-
140% increase of GLP-1 on average Ω
-
92% of participants lost weight, with an average
of 11 pounds ‡
-
92% saw a reduction in total body fat, with up to
a 5.5% decrease ‡
-
71% experienced a reduction in visceral fat, with
up to a 27% decrease ‡
-
100% of subjects who lost weight (92% of total subjects)
maintained or saw an increase in muscle %, with up to a
2.7% increase ‡
-
No side effects were reported, including
gastrointestinal issues*
In addition to these physical results,
participants reported notable changes in their relationship with
food:
-
85% agreed their food cravings decreased*
-
95% agreed their sugar cravings decreased*
-
96% agreed their portion sizes at each meal
decreased*
-
85% agreed they now eat for health, not emotional
reasons*
-
82% felt more in control of their relationship with
food*
“These human clinical results validate our
natural approach to GLP-1 activation, setting us apart from other
products on the market,” said Lisa Barnes, Vice President of
Research and Development at LifeVantage. “We have shown that the
MindBody GLP-1 System activates GLP-1 by a phenomenal 140% on
average and leads to sustainable weight loss combined with
perceptible improvements in cravings and relationships with food.
The results are a testament to our rigorous approach to product
development and showcase our ability to offer activating solutions
that can genuinely transform lives.” ‡ Ω*
The clinical trial builds on successful in vitro
research, which found that the MindBody GLP-1 System significantly
increased GLP-1 production in L-cells by activating key genes. The
in vitro study also revealed a 38% reduction in DPP-4 gene
expression, allowing more GLP-1 to remain active within the body,
and a 53% increase in GLP1R expression, which promotes the creation
of GLP-1 cell receptors, further enhancing the body’s ability to
use GLP-1.§
"LifeVantage is committed to leading the future
of health and wellness by delivering innovative, natural solutions
that truly make a difference," said Steve Fife, CEO of LifeVantage.
"The outstanding success of the MindBody GLP-1 System trial
demonstrates the transformative power of our activation approach,
proving natural GLP-1 activation can not only help people manage
their weight but also significantly enhance their overall health.
Our Consultants are able to change lives and build a thriving
business with this science and innovation.”*
To learn more about the clinical trial findings
or explore how the MindBody GLP-1 System™ can fit into your
wellness routine, visit www.lifevantage.com.
For more information about LifeVantage and its
innovative MindBody GLP-1 System™ visit:
https://www.lifevantage.com/us-en.
About LifeVantage
Corporation
LifeVantage Corporation® (Nasdaq: LFVN), the
Activation company, is a pioneer in nutrigenomics—the study of how
nutrition and naturally occurring compounds can unlock your genes
and the health coded within. Our products work with your unique
biology and help your body make what it needs for health. The line
of scientifically validated activators includes the flagship
Protandim® family of products, TrueScience® Liquid Collagen, the
newest MindBody GLP-1 System™, Activation-supporting nutrients such
as Omega, D3+, and the Rise AM & Reset PM System™, as well as
AXIO® nootropic energy drink mixes, the full TrueScience® line of
skin and hair care products, and Petandim®, a pet supplement
formulated to combat oxidative stress in dogs. Our independent
Consultants sell our products to Customers and share the business
opportunity with entrepreneurs seeking to begin their own sales
business. LifeVantage was founded in 2003 and is headquartered in
Lehi, Utah. For more information,
visit www.lifevantage.com.*
Public Relations Contact: Jennifer Rumble,
CerconeBrownCompany(704) 923-6378 jrumble@cerconebrown.com
Investor Relations Contact: Reed Anderson, ICR
(646) 277-1260 reed.anderson@icrinc.com
*These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat,
cure, or prevent any disease.§Results based on a cell culture study
on active ingredient blends in the MindBody GLP-1 System™.‡Results
may vary. Typical weight loss using this product in a 12-week
weight management program is 1–2 pounds per week. This product
should be used in conjunction with a healthy diet and regular
exercise. Consult with a healthcare provider before starting any
weight loss program. Ω Results based on a randomized 12-week human
clinical study.
Lifevantage (NASDAQ:LFVN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Lifevantage (NASDAQ:LFVN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024